论文部分内容阅读
我们抽取18个药厂生产的四环素糖衣片和11个药厂生产的四环素素片,进行了体外释放度测定。住此基础上,选择6个典型样品,包括糖衣片4个(B、C、D、E),素片2个(F、G)及1个对照溶液剂 A(盐酸四环素),给人服用后,进行血药浓度和尿药浓度测定。通过数据处理、计算,得出如下结果:(1)6个样品生物利用度为:B75.15%,C57.05%,D79.08%,E39.15%,F87.40%,G81.40%。各样品72小时尿累计排药量与溶液剂对比(即生物利用度),所有样品都与溶液剂有极显著的差异(P<0.01),说明我们所考察的样品,目前尚未达到国外报道的应与溶液剂无显著差异的要求。同时,糖衣片生物利用度
We extracted tetracycline sugar-coated tablets produced by 18 pharmaceutical companies and tetracycline tablets produced by 11 pharmaceutical companies for the in vitro release assay. On this basis, six typical samples were selected, including four sugar coated tablets (B, C, D, E), two plain tablets (F, G) and one control solution A (tetracycline hydrochloride) After the blood concentration and urine concentration determination. Through the data processing and calculation, the following results were obtained: (1) The bioavailability of 6 samples was: B75.15%, C57.05%, D79.08%, E39.15%, F87.40%, G81.40 %. The accumulative amount of urinary excretion of 72 hours urine of each sample was compared with that of the solution (ie, bioavailability), and all the samples showed significant differences (P <0.01) with the solution, indicating that the samples we examined have not yet reached the reported Should be no significant difference with the solution requirements. At the same time, sugar-coated tablets bioavailability